Senior insider sale
Chairman, President & CEO at INTRA-CELLULAR THERAPIES, INC. — senior position signals high conviction
$21.21M
287K shares
MATES SHARON plans to sell 287K shares of INTRA-CELLULAR THERAPIES, INC. valued at approximately $21.21M. Form 144 is a notice of intent to sell restricted or control securities — not a mandatory transaction. This filing provides advance warning of potential selling pressure.
compensation
compensation
| Acquisition Date | Type | Amount Acquired | Gift |
|---|---|---|---|
1/8/2019 | compensation compensation | 70K | — |
| Total | 70K | ||
Completed
Units to sell
35.60K
Market value
$2.58M
Units to sell
32.70K
Market value
$2.38M
Units to sell
40.51K
Market value
$2.98M
Units to sell
22.71K
Market value
$1.69M
Units to sell
28.68K
Market value
$2.13M
Units to sell
39.38K
Market value
$2.94M
Units to sell
53.01K
Market value
$4.01M
Planned — Approximate Date
Units to sell
34.40K
Market value
$2.50M
Units
287K
Value
$21.21M
| Date | Units to Sell | Approx. Market Value | Exchange | Status |
|---|---|---|---|---|
| Completed | ||||
8/29/2024 | 35.60K | $2.58M | — | Completed |
8/28/2024 | 32.70K | $2.38M | — | Completed |
8/27/2024 | 40.51K | $2.98M | — | Completed |
8/26/2024 | 22.71K | $1.69M | — | Completed |
8/23/2024 | 28.68K | $2.13M | — | Completed |
8/22/2024 | 39.38K | $2.94M | — | Completed |
8/21/2024 | 53.01K | $4.01M | — | Completed |
| Planned — Approximate Date | ||||
8/30/2024 | 34.40K | $2.50M | NASDAQ | Planned |
| Total | 287K | $21.21M | ||